Eli Lilly hits $1 trillion market value, a first for a health-care company

Core Insights - Eli Lilly has achieved a market capitalization of $1 trillion, becoming the first health-care company to reach this milestone, typically dominated by technology firms [1] - The company's stock has increased over 36% this year, driven by the success of its weight loss injection Zepbound and diabetes treatment Mounjaro, with demand expected to grow as treatment approvals and insurance coverage expand [2] - Analysts predict that the weight loss drug market could exceed $150 billion by the early 2030s, with Eli Lilly likely to maintain a dominant position [3] Company History and Product Development - Eli Lilly was founded in 1876 and has a long history in diabetes treatment, introducing the first commercial insulin in 1923 [4] - The company became publicly traded in 1952 and has historically relied on successful products, including insulins, Prozac, and the polio vaccine, to drive profits [5] - The approval of tirzepatide (Mounjaro) in May 2022 marked a significant milestone, allowing Eli Lilly to compete with Novo Nordisk's Ozempic in the diabetes market [5] Drug Mechanism and Market Competition - Tirzepatide mimics two gut hormones, GLP-1 and GIP, which help reduce food intake and appetite, while Novo Nordisk's semaglutide (Ozempic) only targets GLP-1 [6] - Mounjaro achieved "blockbuster" status, generating over $1 billion in annual sales during its first full year, and has since been approved for obesity treatment as Zepbound, competing with Novo Nordisk's Wegovy [7]